BiotechTube
Positron

Positron

Fishers, United States· Est.
positron.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Positron is a long-established leader in cardiac PET imaging, with over 40 years of experience in nuclear medicine. The company has evolved from a PET-focused firm to a developer of integrated PET-CT systems, such as the NeuSight 64-slice scanner, targeting the specific needs of cardiology practices. Its business model combines technology sales with unique financial offerings like rental and lease-to-own programs to enhance accessibility. Positron is now expanding its focus to include oncology imaging and pursuing regulatory approvals to enter international markets in Europe and Canada.

CardiologyOncology

Technology Platform

Advanced PET and integrated PET-CT imaging systems, including dedicated cardiac PET (Attrius) and 64-slice PET-CT scanners (NeuSight, Affinity) with specialized software for cardiac and oncology diagnostics.

Opportunities

The clinical superiority of cardiac PET over SPECT and the large, growing oncology imaging market provide significant growth avenues.
Positron's flexible rental and lease-to-own business model can drive adoption in cost-conscious segments like outpatient clinics and community hospitals, differentiating it from competitors.

Risk Factors

Intense competition from large, well-capitalized global imaging corporations (Siemens, GE, Philips) poses a major threat.
Execution risks include delays in launching the Affinity system and challenges in gaining market acceptance in oncology.
The company is also exposed to reimbursement changes and credit risks inherent in its financing model.

Competitive Landscape

Positron competes in the high-end medical imaging market dominated by multinational conglomerates like Siemens Healthineers, GE HealthCare, and Philips. Its primary competitive advantage is deep specialization in cardiac PET, offering tailored solutions and flexible financing. In the broader PET-CT space, it must compete on technology performance, reliability, and service against these giants with far greater resources.

More companies in Diagnostics & Precision Medicine →More companies in United States →